i have been following mnkd tradings for the last 3 weeks, all I see is 100 shares thrown 1 penny above the asking to stop any form of a rally. If they see any sign of a possible surge, they will throw in 100-200k shares to completely put out the fire. If you look at the short shares; they added 3 million shares under $1 to control the price. Thus, you know the shorts want to kill this company.
The shorts are committed and they will do anything to keep this under $1, avoiding any possiblity of secondary offerings to generate money for the company. They want to do everything possible to BK this company, including delisting from Nasdaq etc, etc. Thus, management has to come in and kill these shorts; there is no long term struggle here folks. By april we will either see fireworks and dud
So SNY just wasted a year doing this slow controlled launch, where each year they can potentially lose $5-6 billion (projected income) when they delay the launch. Something has gotta give; can't slow play Afrezza too long.
so you are saying SNY spent $200 mil ($150 upfront and $50 mil milestone) and walked away from the deal, only after 4 months of "launch" without the docs, the patients, or insurance companies knowing about Afrezza? Gee, I didn't know SNY has that kind of cash to be throwing around.
the cost is similar to injectibles. So, patients would prefer needles to inhalation? Still boils down to SNY's duty to reach docs and insurances tier 2 coverages.
that's SNY influence and their duty, so why aren't they getting enough tiers 2? But there are now several tiers 2 coverages to earn much better scripts but why not? It comes down to SNY (not teaching docs and not getting enough tiers 2). Why only several tiers 2? if you can convince 3 insurance companies for tiers 2, then you can convince the rest.
you have access to the internet and docs, try calling 100 of docs and see how many actually know about Afrezza. You will be lucky if you encounter just ONE.
we are all in it to make money, no grudges. The short coverings from the lows will help share price to a higher peaks. Example, if they start covering now, they will make some profits and use that money to buy back even at a higher price, and it peaks even higher highs. Everyone wins, even the shorts. But if we go against each other, then everyone loses. 500% spike from $7 is better than 500% spike from $2.
it's a new drug, if you don't tell the docs about a new drug or technology, they will never know. 99.999% of docs retain only what they learned in Med school and residency; new materials have to be brought to them.
you are in denial if you think that 500,000 docs to 30 million patients, and they maxed out at 600 pt/wk, every week for the last 4 months, isn't sand bagging. Snap out of it, you are not thinking straight.
BTW, they told you it is a "controlled launch". which part of that did you not understand?
If they had a real launch then I would take your words for Afrezza failure. But if you asked around pharmacies, doctors, and patients and most (if not all) have said they have not heard of Afrezza, then it hasn't really launched yet.
You are making the assumption that they launched and failed. I am saying all they did was a trial launch with selected group of docs and patients; thereby, SNY has achieved cheap mnkd shares and they have a better idea on how Afrezza is doing in a controlled market.
you can hire a 12 yo kid to easily kill something but if you want success you hire an expert. So, you think, the new CEO was hired to kill Afrezza because he was one of the leaders in failing Exubera? I think it is more like, he was hired because of his experience in launching inhale insulin, he knew why it failed, now he can do a better job.
Don't know Jason Karp, small potato. Einhorn is among Carl Icahn's elite, and they still get slaughtered.
My suggestion for the shorts, don't get too cocky or comfortable with your short positions. You have made some profits, get out while you can. Mnkd is an extremely dangerous short. There are 20 years to every drug patent, a lot of time left. When a launch isn't really a launch, you have to wonder, what else is lurking in the silence. YOur portfollios can be wiped out. David Einhorn's portfollio suffered 20% down due to Green Mt short; he was most likely in the 10-20% positive if it had not been for his bad short position.
NO, the 500,000 is the approximate number of internists, family practitioners, and endocrinologists. I only included the docs who will most likely be prescribing Afrezza. These are just the generalists and endos.
The question is what happened there? Was there a conflict between Mnkd and SNY? Was there another buyer that Mnkd wanted to sell to that angered SNY? Clearly if Mnkd was actively still searching for a buyer while they were still in a partnership with SNY, this would prevent SNY from fully spending a lot of money on Ads and sales. Just like any relationship, if a girl you are dating is actively dating other guys, would you put much effort into the girl? The same difference. Hence, SNY stopped pushing Afrezza. It is evidenced that the number of scripts plateaus around 500-600/wk which means that the number of prescribers has also remained constant since July/August of 2015.
There are 500,000 doctors in the US and the number of diabetes is around 30 million in the US. Thus, getting 500-600/wk of scripts does not make any sense. Hold and add more shares, the show has not started yet and most investors think it is over.
if you noticed the number of scripts each month plateaus at 500-600/wk. There are 30 million diabetics in the US and 500,000 docs who can prescribe. The question is why did SNY stop pushing Afrezza?